US Hemorrhoids Treatment Market is predicted to reach USD 1.534 Billion at a CAGR of 4.58% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global US Hemorrhoids Treatment Market”.

The Sentinel Node Biopsy Market is estimated to register a CAGR of 4.95% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the US Hemorrhoids Treatment market— Medtronic Plc (Ireland), CONMED Corporation (US), Cook Medical (US), Pfizer Inc (US), Abbott Laboratories (US), Boston Scientific Corporation (US), Integra LifeSciences (US), Sklar Surgical Instruments (US), Privi Medical (US), Olympus Corporation (Japan).

US Hemorrhoids Treatment Market Highlights

The US Hemorrhoids Treatment market registered a CAGR of 4.58% during the forecast period and is estimated to reach USD 1.534 Billion by 2032.

The US Hemorrhoids Treatment Market is experiencing robust growth, fueled by several factors contributing to increased demand for effective solutions. The market's expansion is notably driven by a rising incidence of hemorrhoidal disorders, propelled further by lifestyle factors and an aging demographic. As the prevalence of this condition continues to climb, pharmaceutical and non-pharmaceutical interventions are witnessing a surge in demand. The market landscape is marked by advancements in minimally invasive procedures, topical medications, and sophisticated surgical techniques, providing patients with a range of treatment options. The growth trajectory is further supported by heightened awareness regarding the importance of early intervention and the availability of over-the-counter treatments. Analysts anticipate sustained market growth and emphasize the significance of technological innovations and strategic collaborations among industry players. The integration of cutting-edge technologies and partnerships can enhance product portfolios, ensuring a competitive advantage in this dynamically evolving healthcare sector. Overall, the US Hemorrhoids Treatment Market is positioned for continued expansion, driven by a confluence of demographic trends, technological advancements, and proactive healthcare initiatives.

Analyst Viewpoint:

The US hemorrhoids treatment Market is witnessing significant growth, driven by a surge in the prevalence of hemorrhoidal disorders and an aging population. It projects a steady rise in demand for both pharmaceutical and non-pharmaceutical interventions. The market is characterized by innovations in minimally invasive procedures, topical medications, and advanced surgical techniques. Increasing awareness about the importance of early intervention and the availability of over-the-counter treatments further contribute to market expansion.

Segment Analysis

The US hemorrhoid treatment market has been segmented based on product type, technology, Indication, and end user.

Based on type, the market is segmented including External Hemorrhoids, Internal Hemorrhoids, and Prolapsed Hemorrhoids. The Internal Hemorrhoids segment holds the majority share in 2022 in the US Hemorrhoids Treatment market revenue. This is because of the aging population, there is an increasing prevalence of internal hemorrhoids, spurring demand for effective remedies. Heightened awareness and education contribute to a proactive approach among individuals seeking treatment. Advances in medical technologies and a trend favoring minimally invasive procedures, such as rubber band ligation and infrared coagulation, are shaping the landscape. Additionally, the availability of over-the-counter products underscores a broader market for self-management. Monitoring these trends will provide a comprehensive understanding of the evolving landscape of internal hemorrhoid treatments and their continued growth in the US.

Further, we estimate that the market segment will continue to pool in the largest chunk of revenue during the forecast period. It has been identified that the segment market yet witnesses continuous innovations and movements in terms of new product therapy and services.

On the basis of treatment type, the market is bifurcated into surgical, and nonsurgical. The S non-surgical segment was attributed to holding the largest market share in 2022.

Based on specialists, the market is segmented into proctologist, general physician, gastroenterologist, and others. The proctologist segment was attributed to holding the largest market share in 2022.

On the basis of the end user, the market is segmented into Hospital & clinics, Ambulatory surgical centers, and Others. The Hospitals and Clinics segment is projected to have the largest market share during the forecast period.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of US Hemorrhoids Treatment Market Research Report

Country Analysis

The US Hemorrhoids Treatment market is growing due to a rising prevalence of hemorrhoids, particularly among an aging demographic, and the demand for effective treatments is increasing. The market's trajectory is shaped by advancements in medical technologies, a trend towards less invasive procedures, and the expertise of proctologist specialists. Additionally, hospitals and clinics play a crucial role in providing comprehensive care, offering a range of treatment options, and contributing significantly to the market's expansion. Increased awareness, education, and the availability of over-the-counter products further bolster the growth of the hemorrhoids treatment market, creating a dynamic landscape in the United States.

Key Findings of the Study

• The global healthcare counseling market is expected to reach USD 1.534 Billion by 2032, at a CAGR of 4.58% during the forecast period.


• Based on specialists, the proctologist segment was attributed to holding the largest market in 2022, with an approximate market share of 35–40%.


• Medtronic Plc (Ireland), CONMED Corporation (US), Cook Medical (US), Pfizer Inc (US), Abbott Laboratories (US), Boston Scientific Corporation (US), Integra LifeSciences (US), Sklar Surgical Instruments (US) Privi Medical (US), Olympus Corporation (Japan) are the key market players.